Allegro Ophthalmics to Present Clinical Research on the Company’s Novel Integrin-Regulating Portfolio at the American Academy of Ophthalmology Annual Meeting

October 8, 2019 Off By BusinessWire

AAO 2019 To Feature Multiple Presentations by Leading Experts on Allegro’s Dry Age-Related Macular Degeneration and Dry Eye Disease Assets

SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–#AAO2019—Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel therapies that regulate select integrin functions for the treatment of ocular diseases, today announced that the results of its US Phase 2 clinical study of risuteganib (Luminate®) for the treatment of intermediate nonexudative age-related macular degeneration (dry AMD) will be presented during AAO 2019, the American Academy of Ophthalmology’s 123^rd annual meeting that is being held October 11- 15 in San Francisco, CA.

On Thursday, October 10, Allegro’s President and CEO Vicken Karageozian, M.D., will provide an overview on the company’s portfolio of integrin-regulating therapies for dry AMD and dry eye disease at the Ophthalmology Innovation Summit (OIS). On Friday, October 11 during Retina Subspecialty Day, David S. Boyer, M.D., will present the primary visual acuity results of the risuteganib US Phase 2 clinical trial for intermediate dry AMD at AAO 2019. An ePoster authored by Glenn J. Jaffe, M.D., on the same study also will be available for viewing.

In June, Allegro announced topline results of its first Phase 2a intermediate dry AMD clinical trial in 45 study subjects. This is the first study to demonstrate reversal of vision loss in dry AMD. The study met its primary endpoint with 48 percent of patients in the risuteganib arm at week 28 gaining ≥ 8 letters from baseline, compared to 7 percent of patients in the sham group at week 12 (p=0.013). Risuteganib was found to be safe with no drug related serious adverse events (SAEs). In addition to best corrected visual acuity (BCVA), secondary outcomes for several patient cases will be presented at AAO 2019.

In addition to the risuteganib Phase 2 intermediate dry AMD data, on Saturday, October 12, Richard L. Lindstrom, M.D., will present the results of its ALG-1007 ex-U.S. proof-of-concept trial for the treatment of dry eye disease.

“We are excited to present the progress of our portfolio of integrin-regulating drug candidates to the clinical community at AAO 2019 and OIS,” said Dr. Karageozian. “We recently presented the clinical outcomes of our risuteganib Phase 2a intermediate dry AMD trial to the FDA and I’m pleased to report that Allegro has a clear path forward. We are now working closely with our scientific advisory board to prepare for a larger US Phase 2b/3 trial. In addition, we continue to advance our ALG-1007 dry eye program.”

The corporate and scientific presentations are scheduled as follows:

Thursday, October 10: 8:54-9:01 AM

Ophthalmology Innovation Summit, Hilton San Francisco Union Square

A Novel Integrin-Regulating Portfolio for Front and Back of the Eye Diseases.

Vicken Karageozian, M.D.

Friday, October 11: 4:42-4:47 PM

AAO 2019, Moscone Center, West 3002, San Francisco

Primary Results from Phase 2 Study of Risuteganib (RSG) in Intermediate Dry Age-Related Macular Degeneration (dAMD). David S. Boyer, M.D.

Saturday, October 12: 1:15-1:45 PM

AAO 2019, Moscone Center, Station 3, San Francisco (ePoster Discussion)

A Pilot Study to Evaluate the Safety and Exploratory Efficacy of ALG-1007 Topical Ophthalmic Solution for the Treatment of Dry Eye Disease. Richard L. Lindstrom, M.D.

AAO 2019, Moscone Center, San Francisco (ePoster)

Safety and Efficacy of Risuteganib in Non-Exudative Age-Related Macular Degeneration.

Glenn J. Jaffe, M.D.

About Allegro Ophthalmics, LLC

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel integrin-regulating therapies for the treatment of ocular diseases. Pre-clinical data suggest that risuteganib (Luminate®), Allegro’s lead investigational compound in retina, simultaneously acts on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry AMD and diabetic macular edema (DME). A U.S. Phase 2a study with risuteganib in intermediate dry AMD was recently completed. Two Phase 2 DME studies also have been successfully completed. Expanding its integrin-regulating portfolio, Allegro has developed ALG-1007, an integrin-regulating drug candidate for topical use in dry eye disease. ALG-1007 has successfully completed an ex-U.S. proof-of-concept study in humans, and is currently being evaluated in a larger ex-U.S. Phase 2 study. For more information, visit www.allegroeye.com.

Luminate® is a registered trademark of Allegro Ophthalmics, LLC.